+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Icosapent Ethyl Drugs Market by Dosage Form (Softgel Capsule), Route of Administration (Oral), Strength, Application, Distribution Channel, Patient Age Group, End-User - Global Forecast 2025-2030- Product Image
Icosapent Ethyl Drugs Market by Dosage Form (Softgel Capsule), Route of Administration (Oral), Strength, Application, Distribution Channel, Patient Age Group, End-User - Global Forecast 2025-2030- Product Image
New

Icosapent Ethyl Drugs Market by Dosage Form (Softgel Capsule), Route of Administration (Oral), Strength, Application, Distribution Channel, Patient Age Group, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6123049
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Icosapent ethyl has emerged as a transformative agent in cardiovascular therapeutics, bridging the gap between lipid-modifying interventions and comprehensive risk reduction strategies. Its molecular formulation, refined through decades of marine hydroxyl acid research, positions it at the forefront of modern disease management. Clinical studies have underscored its ability to lower triglyceride levels while conferring anti-inflammatory and plaque-stabilizing effects. As practitioners embrace a more holistic approach to cardiovascular wellness, icosapent ethyl’s mechanism of action aligns seamlessly with evolving treatment paradigms that prioritize both efficacy and safety.

Against this backdrop, stakeholders across the healthcare continuum-from pharmaceutical innovators to regulatory bodies-are refining their focus on patient outcomes and economic value. The confluence of rigorous clinical validation, shifting reimbursement models, and a heightened emphasis on preventative care has propelled icosapent ethyl into the spotlight. This introduction frames the broader context in which this executive summary resides, setting the stage for a deep exploration of market forces, regulatory shifts, segmentation dynamics, and regional nuances that will inform actionable strategies.

Explore how converging technological innovations regulatory advancements and patient-centric models are redefining the icosapent ethyl pharmaceutical landscape and unlocking new therapeutic potential

In recent years, the pharmaceutical ecosystem surrounding icosapent ethyl has undergone a profound metamorphosis driven by scientific breakthroughs, regulatory milestones, and evolving patient expectations. Breakthrough research in lipidomics has illuminated previously unrecognized pathways through which omega-3 derivatives exert cardioprotective effects, prompting regulatory agencies to expand labeling claims and streamline approval processes. Concurrently, the integration of digital health tools has empowered patients to engage more actively in their treatment regimens, fostering adherence and enabling remote monitoring of lipid profiles and inflammatory markers.

Moreover, advances in green chemistry have optimized extraction and purification processes for eicosapentaenoic acid, reducing reliance on volatile solvents and improving supply chain sustainability. This shift has been bolstered by strategic alliances between marine biotechnology firms and established pharmaceutical manufacturers, catalyzing capacity expansion and enhancing scale efficiencies. Together, these developments are reshaping how stakeholders conceive, develop, and deliver icosapent ethyl therapies, setting a new standard for evidence-based personalization in cardiovascular risk management.

Assess the multifaceted implications of the 2025 United States tariff adjustments on raw material sourcing manufacturing cost dynamics and distribution strategies within the icosapent ethyl sector

The introduction of revised United States tariffs in 2025 has introduced a layer of complexity to the icosapent ethyl supply chain, affecting every link from raw material procurement to end-user pricing. Marine-derived fatty acids, often sourced internationally, now face elevated import duties that have ripple effects on manufacturing cost structures. In response, producers have initiated regionally diversified sourcing strategies, negotiating long-term supply agreements and exploring alternative feedstocks such as algae-derived omega-3 to mitigate tariff exposure.

Simultaneously, intermediate costs linked to specialized excipients and packaging materials have risen, prompting manufacturers to re-evaluate contract terms with chemical suppliers and to optimize production schedules for greater batch yields. Distribution partners have similarly adjusted freight models, leveraging blended logistics networks to alleviate price pressure passed down to hospital pharmacies, retail outlets, and online channels. While short-term cost increases posed challenges for payers and patients, market participants are collaborating on value-based contracting frameworks to align reimbursement with clinical outcomes, smoothing the path to sustained access and affordability.

Unveil critical segmentation perspectives spanning formulation administration strength application distribution patient demographics and care settings within the icosapent ethyl domain

The icosapent ethyl market is predominantly characterized by its softgel capsule formulation, leveraging a tolerable dosage format that facilitates oral administration and supports consistent patient adherence. Within this framework, standardized strength offerings of 1000 mg and 500 mg enable prescribers to tailor therapy regimens according to individual triglyceride profiles and cardiovascular risk factors. The oral route of delivery streamlines treatment integration for adult and geriatric populations, who can seamlessly incorporate capsules into established medication routines alongside statins or antiplatelet agents.

Application areas span primary lipid-lowering to adjunctive strategies targeting cardiovascular risk reduction, as well as focused management of hypertriglyceridemia. Distribution pathways remain diverse, traversing hospital pharmacies, online pharmacy platforms, and retail chains, which collectively ensure broad patient access regardless of treatment setting. End-user environments vary from outpatient clinics and home care scenarios to inpatient hospital wards, reflecting the therapy’s versatility across acute interventions and chronic management. By understanding these layered segmentation dynamics, stakeholders can refine market entry plans, optimize supply networks, and craft targeted communications for each demographic and care context.

Illuminate regional market dynamics and contextual nuances across the Americas EMEA and Asia Pacific that influence the adoption and distribution of icosapent ethyl therapeutics

Across the Americas, strong regulatory support and comprehensive insurance frameworks have accelerated prescription uptake of icosapent ethyl for both primary and secondary prevention. North American markets demonstrate robust clinician engagement, supported by extensive post-marketing studies and real-world evidence registries. In contrast, Latin American countries are navigating unique reimbursement models, driving partnerships between local distributors and global pharmaceutical firms to expand public and private coverage schemes.

Within Europe, the Middle East, and Africa, regional heterogeneity in regulatory pathways and healthcare infrastructure shapes divergent adoption rates. Western European nations often align with stringent EMA guidelines, fostering earlier market access and value-based agreements, while emerging markets in Eastern Europe and parts of the Middle East prioritize cost-effective generic alternatives. Meanwhile, Africa’s nascent pharmaceutical networks are gradually integrating icosapent ethyl through multinational collaborations and donor-supported programs.

In the Asia Pacific region, dynamic demographic shifts and rising cardiovascular disease burden have spurred regulatory prioritization of innovative therapies. Markets in Japan and Australia exhibit advanced clinical guideline updates that incorporate icosapent ethyl, whereas Southeast Asian and South Asian nations are charting phased rollout strategies, balancing cost containment with aspirational health outcomes targets.

Highlight strategic initiatives research collaborations and competitive tactics undertaken by leading pharmaceutical and biotech companies within the icosapent ethyl sector

Amarin Corporation remains the pioneer and market leader in icosapent ethyl commercialization, leveraging its extensive clinical trial portfolio and patent exclusivity to maintain premium positioning. The company’s strategic investments in real-world outcomes research and digital patient support programs reinforce its brand loyalty among cardiologists and endocrinologists. Concurrently, established pharmaceutical giants have entered collaborative licensing agreements to expand manufacturing capacity and co-market in select territories, aiming to capture incremental market share ahead of patent expiry timelines.

Biotech firms are intensifying R&D efforts to develop next-generation omega-3 derivatives with enhanced bioavailability or targeted delivery systems. Partnerships between contract development organizations and specialty pharmaceutical players have accelerated scale-up processes, enabling rapid response to supply fluctuations induced by geopolitical factors. Generic drug manufacturers are also preparing for market entry with bioequivalent softgel capsules, positioning competitive pricing strategies to address cost-sensitive segments. Together, these corporate maneuvers illustrate a competitive landscape in which innovation, alliance formation, and lifecycle management converge to shape the future of icosapent ethyl offerings.

Deliver actionable strategic initiatives that empower industry stakeholders to enhance patient engagement optimize supply chain resilience and advance clinical differentiation in the icosapent ethyl landscape

Industry leaders should prioritize the expansion of patient-centered support platforms that integrate telehealth consultations and mobile adherence tracking to bolster real-world effectiveness. By forging strategic alliances with specialty pharmacies and digital therapeutics providers, organizations can cultivate differentiated value propositions that extend beyond traditional prescribing channels. Concurrently, aligning with policy makers to pilot outcome-linked reimbursement frameworks will enhance stakeholder confidence in therapy affordability and long-term health economic benefits.

Supply chain resilience should be reinforced through diversified raw material sourcing combined with predictive demand planning driven by advanced analytics. Investing in sustainable extraction methods and circular packaging solutions will not only mitigate tariff impacts but also align with corporate responsibility goals. Finally, steering future research toward biomarker-driven patient stratification and combination therapy studies can unlock novel clinical pathways, propelling icosapent ethyl into new therapeutic frontiers and consolidating market leadership.

Detail the comprehensive research methodology integrating secondary literature review primary expert interviews and analytical frameworks that underpin our insights into the icosapent ethyl market

This analysis synthesizes data derived from a rigorous research framework combining in-depth secondary research and targeted primary interviews. Secondary sources encompassed peer-reviewed clinical journals regulatory filings from the FDA and EMA, company annual reports, and public policy documents. These datasets were systematically validated through cross-referencing and gap analysis to ensure consistency in drug approval timelines, tariff legislation, and clinical guideline updates.

Complementing this, primary engagements with key opinion leaders including cardiologists lipidologists regulatory experts and supply chain executives provided nuanced perspectives on evolving market drivers and adoption barriers. Qualitative insights were triangulated with quantitative metrics to construct a holistic view of competitive dynamics and segmentation trends. Analytical methods incorporated scenario planning, sensitivity testing of tariff variables, and PESTLE assessments to reveal how macroeconomic and regulatory forces intersect with therapeutic innovation in shaping the icosapent ethyl market.

Synthesize key findings and underscore the overarching themes of innovation regulatory adaptation and patient outcome optimization within the icosapent ethyl therapeutic landscape

The confluence of clinical validation, regulatory developments, and strategic corporate initiatives has propelled icosapent ethyl to the forefront of cardiovascular therapeutics. Segmentation analyses underscore the critical interplay between formulation design, dosing flexibility, and distribution networks in driving patient access. Regional snapshots reveal diverse adoption patterns shaped by reimbursement landscapes and healthcare infrastructure, while tariff revisions in the United States highlight the importance of supply chain agility and value-based contracting.

Leading companies are navigating a dynamic competitive arena through targeted R&D collaborations, lifecycle extension strategies, and innovative patient support models. Actionable recommendations emphasize the need for digital integration, sustainable sourcing, and policy engagement to ensure both clinical and commercial success. Underpinning these insights, a robust research methodology offers confidence in data integrity and analytical rigor. Together, these findings chart a clear roadmap for stakeholders aiming to harness the full potential of icosapent ethyl and elevate patient outcomes.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Dosage Form
    • Softgel Capsule
  • Route Of Administration
    • Oral
  • Strength
    • 1000 Mg
    • 500 Mg
  • Application
    • Cardiovascular Risk Reduction
    • Hypertriglyceridemia
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Age Group
    • Adult
    • Geriatric
  • End-User
    • Clinic
    • Home Care
    • Hospital
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Amarin Corporation plc
  • Par Pharmaceutical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy’s Laboratories (USA) Inc.
  • Aurobindo Pharma USA Inc.
  • Sandoz Inc.
  • Cipla USA Inc.
  • Apotex Corp.
  • Cadila Healthcare Ltd

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of icosapent ethyl as an adjunct therapy in high-risk cardiovascular patient populations
5.2. Emergence of generic competitors challenging Amarin’s market share in the icosapent ethyl segment
5.3. Regulatory expansion of approved indications for icosapent ethyl beyond triglyceride reduction
5.4. Rising payer negotiations and formulary placements impacting patient access to icosapent ethyl
5.5. Integration of icosapent ethyl into guideline-recommended lipid management protocols worldwide
5.6. Development of novel delivery formulations for icosapent ethyl to enhance patient adherence
5.7. Strategic partnerships between biopharma companies to co-promote icosapent ethyl in emerging markets
5.8. Impact of price rebates and copay assistance programs on icosapent ethyl prescription volumes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Icosapent Ethyl Drugs Market, by Dosage Form
8.1. Introduction
8.2. Softgel Capsule
9. Icosapent Ethyl Drugs Market, by Route of Administration
9.1. Introduction
9.2. Oral
10. Icosapent Ethyl Drugs Market, by Strength
10.1. Introduction
10.2. 1000 Mg
10.3. 500 Mg
11. Icosapent Ethyl Drugs Market, by Application
11.1. Introduction
11.2. Cardiovascular Risk Reduction
11.3. Hypertriglyceridemia
12. Icosapent Ethyl Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Icosapent Ethyl Drugs Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Geriatric
14. Icosapent Ethyl Drugs Market, by End-User
14.1. Introduction
14.2. Clinic
14.3. Home Care
14.4. Hospital
15. Americas Icosapent Ethyl Drugs Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Icosapent Ethyl Drugs Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Icosapent Ethyl Drugs Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Amarin Corporation plc
18.3.2. Par Pharmaceutical Inc.
18.3.3. Teva Pharmaceutical Industries Ltd.
18.3.4. Viatris Inc.
18.3.5. Dr. Reddy’s Laboratories (USA) Inc.
18.3.6. Aurobindo Pharma USA Inc.
18.3.7. Sandoz Inc.
18.3.8. Cipla USA Inc.
18.3.9. Apotex Corp.
18.3.10. Cadila Healthcare Ltd
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. ICOSAPENT ETHYL DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ICOSAPENT ETHYL DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ICOSAPENT ETHYL DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 29. ICOSAPENT ETHYL DRUGS MARKET: RESEARCHAI
FIGURE 30. ICOSAPENT ETHYL DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 31. ICOSAPENT ETHYL DRUGS MARKET: RESEARCHCONTACTS
FIGURE 32. ICOSAPENT ETHYL DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ICOSAPENT ETHYL DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SOFTGEL CAPSULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY SOFTGEL CAPSULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY 1000 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY 1000 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY 500 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY 500 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CARDIOVASCULAR RISK REDUCTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HYPERTRIGLYCERIDEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 83. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 84. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 85. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 88. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 89. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 90. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 91. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 94. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 95. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 96. CANADA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 97. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 98. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 99. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 102. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 103. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 104. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 105. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 106. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 107. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 110. MEXICO ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 127. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 156. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 158. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 169. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 170. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 171. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 174. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 175. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 182. GERMANY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 183. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 184. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 185. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 188. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 189. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 190. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 191. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 194. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 195. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 196. FRANCE ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 197. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 198. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 199. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 211. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 212. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 213. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 216. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 217. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 222. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 223. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 224. ITALY ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 225. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 226. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 227. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 230. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 231. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 232. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 233. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 236. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 237. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 238. SPAIN ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 254. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 268. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 281. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 282. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 283. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 286. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 287. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 292. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 293. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 294. DENMARK ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 295. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 296. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 297. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 300. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 301. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 302. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 309. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 310. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 311. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 312. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 313. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 314. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 315. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 316. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 317. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 318. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 319. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 320. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 321. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 322. QATAR ICOSAPENT ETHYL DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 323. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
TABLE 324. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2030 (USD MILLION)
TABLE 325. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 326. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 327. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2018-2024 (USD MILLION)
TABLE 328. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY STRENGTH, 2025-2030 (USD MILLION)
TABLE 329. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 330. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 331. FINLAND ICOSAPENT ETHYL DRUGS MARKET SIZE, BY DIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Icosapent Ethyl Drugs market report include:
  • Amarin Corporation plc
  • Par Pharmaceutical Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy’s Laboratories (USA) Inc.
  • Aurobindo Pharma USA Inc.
  • Sandoz Inc.
  • Cipla USA Inc.
  • Apotex Corp.
  • Cadila Healthcare Ltd

Related Topics

Related Reports

Severe Hypertriglyceridemia Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Severe Hypertriglyceridemia Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 138 Pages
  • Global
From
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia - Pipeline Insight, 2025 - Product Image

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Cardiovascular Risk Reduction Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, and Product Type - Product Image

Cardiovascular Risk Reduction Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, and Product Type

  • Report
  • 106 Pages
  • Global
From
LDL-C Lowering Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type - Product Image

LDL-C Lowering Therapeutics Global Market Insights 2024, Analysis and Forecast to 2029, by Market Participants, Regions, Technology, Product Type

  • Report
  • 107 Pages
  • Global
From
Pulmonary Hypertension - Pipeline Insight, 2025 - Product Image

Pulmonary Hypertension - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.